Galderma Group AG (GALD)

Currency in CHF
166.55
+4.40(+2.71%)
Closed·
GALD is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
163.05168.00
52 wk Range
107.40171.90
Key Statistics
Bid/Ask
162.00 / 167.00
Prev. Close
162.15
Open
163.95
Day's Range
163.05-168
52 wk Range
107.4-171.9
Volume
1.62M
Average Volume (3m)
1.15M
1-Year Change
58.7703%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GALD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
183.13
Upside
+9.95%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Galderma Group AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

14 Buy
3 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 183.13
(+9.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Hold160.00-3.93%155.00MaintainApr 27, 2026
Citi
Buy185.00+11.08%165.00MaintainApr 24, 2026
Berenberg
Buy200.00+20.08%187.00MaintainMar 31, 2026
Citi
Buy165.00-0.93%-New CoverageMar 26, 2026
Morgan Stanley
Hold155.00-6.93%145.00MaintainMar 09, 2026

Galderma Group AG Earnings Call Summary for Q1/2026

  • Galderma reported Q1 2026 net sales of $1.473B, up 25.5% YoY; EPS of $1.12 met expectations; stock surged 5.11% to $158.45
  • Injectable Aesthetics generated $648M (13.1% growth); Dermatological Skincare reached $441M (17% growth), driving overall performance
  • CEO Dittrich emphasized innovation and market expansion; incoming CFO La Corte highlighted strong financial position for growth opportunities
  • Company issued optimistic 2026 guidance with projected EPS growth, new injectable aesthetics launches, and international market expansion planned
  • Key risks include FX fluctuations impacting EBITDA, tariff pressures, market saturation, supply chain complexities, and competitive pressures
Last Updated: 04/23/2026, 10:38 PM
Read Full Transcript

Earnings

Latest Release
Apr 23, 2026
EPS / Forecast
1.14 / --
Revenue / Forecast
1.47B / 1.47B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.58%
Dividend Yield
0.22%
Industry Median 2.40%
Annualized payout
0.35
Paid unevenly
5-Years Growth
-
Growth Streak

GALD Income Statement

Compare GALD to Peers and Sector

Metrics to compare
GALD
Peers
Sector
Relationship
P/E Ratio
83.8x25.8x−0.5x
PEG Ratio
0.490.440.00
Price/Book
6.3x3.6x2.6x
Price / LTM Sales
9.8x4.1x3.1x
Upside (Analyst Target)
13.1%13.1%50.7%
Fair Value Upside
Unlock10.9%7.6%Unlock

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
66.80M28.48%10.87B
Other Institutional Investors
191.12M71.52%31.11B
Public Companies & Retail Investors
0.000.00%0.00
Total
257.93M100.00%41.98B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
L'Oréal S.A.20.28%47,579,5287,715,020
Eqt Fund Management S.à R.L.15.27%35,827,5605,809,439

People Also Watch

52.10
ALCC
+0.73%
827.20
PGHN
-0.70%
65.60
SDZ
+0.43%
117.82
NOVN
-0.37%
153.30
SIKA
+0.59%

FAQ

What Is the Galderma (GALD) Stock Price Today?

The Galderma stock price today is 166.55 CHF.

What Stock Exchange Does Galderma Trade On?

Galderma is listed and trades on the Switzerland Stock Exchange.

What Is the Stock Symbol for Galderma?

The stock symbol for Galderma is "GALD."

Does Galderma Pay Dividends? What’s The Current Dividend Yield?

The Galderma dividend yield is 0.21%.

What Is the Galderma Market Cap?

As of today, Galderma market cap is 39.07B CHF.

What Is Galderma's Earnings Per Share (TTM)?

The Galderma EPS (TTM) is 2.58.

When Is the Next Galderma Earnings Date?

Galderma will release its next earnings report on Jul 23, 2026.

From a Technical Analysis Perspective, Is GALD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Galderma Stock Split?

Galderma has split 0 times.

How Many Employees Does Galderma Have?

Galderma has 7676 employees.

What is the current trading status of Galderma (GALD)?

As of May 30, 2026, Galderma (GALD) is trading at a price of 166.55 CHF, with a previous close of 162.15 CHF. The stock has fluctuated within a day range of 163.05 CHF to 168.00 CHF, while its 52-week range spans from 107.40 CHF to 171.90 CHF.

What Is Galderma (GALD) Price Target According to Analysts?

The average 12-month price target for Galderma is 183.13 CHF, with a high estimate of 259.26634269 CHF and a low estimate of 113.02633642 CHF. 14 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +9.95% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.